Minimum Investment
About Company
Company Name: Bio-Medica Laboratories Limited
Industry / Sector: Pharmaceuticals - Injectable Formulations (Parenteral)
Founded Year: 2015
Promoters: Mr. Mukesh Mehta, Mr. Pradeep Mehta
Bio-Medica Laboratories Limited is engaged in the manufacturing and trading of pharmaceutical parenteral formulations (injectables). The company produces a wide range of ethical drugs, generic drugs, and OTC medications in liquid and dry powder injectable forms for human and veterinary use. It operates on a B2B contract manufacturing model and holds GMP & GLP certifications from the Food & Drugs Administration, Madhya Pradesh. The company has two manufacturing facilities in Indore, Madhya Pradesh.
IPO Basic Details
| Company Name | Bio-Medica Laboratories Limited |
| IPO Type | SME IPO |
| Price Band | ₹132 – ₹139 |
| Lot Size | 1000 |
| Total Issue Size | ₹52.43 Cr (37,72,000 shares) |
IPO Strengths & Risks
Strengths
- Multi-product manufacturing capability
- GMP & GLP certified facilities
- Experienced promoters and team
- Quality assurance focus
Risks
- Highly competitive and fragmented pharma segment
- Regulatory risks
- Raw material price volatility
IPO Important Dates
| IPO Open Date | 21 May 2026 |
| IPO Close Date | 25 May 2026 |
| Basis of Allotment | 26 May 2026 |
| Refund Initiation | 27 May 2026 |
| Demat Credit Date | 27 May 2026 |
| Listing Date | 29 May 2026 |
| Anchor Investor Date | - |
| UPI Mandate Deadline | - |
IPO Objectives
- Capital expenditure for machinery and equipment – -
- Funding working capital requirements – -
- Debt repayment – -
- General corporate purposes – Balance amount
Investor Reservation
| QIB Quota | 1.00% |
| Retail Quota | 50.01% |
| HNI Quota | - |
| Employee Quota | - |
| Shareholder Quota | - |
| Anchor Investor Allocation | - |
Market Lot Details
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 lots | 2000 | ₹2,78,000 |
| Retail Maximum | - | - | - |
| S-HNI Minimum | 3 lots | 3000 | ₹4,17,000 |
| S-HNI Maximum | - | - | - |
| B-HNI Minimum | 8 lots | 8000 | ₹11,12,000 |
Key Performance Indicators (KPI)
| ROE | 54.41% (30 Nov 2025) / 99.59% (31 Mar 2025) |
| ROCE | 23.22% (30 Nov 2025) / 48.20% (31 Mar 2025) |
| RoNW | - |
| PAT Margin | 30.35% (30 Nov 2025) / 25.64% (31 Mar 2025) |
| EBITDA Margin | 47.11% (30 Nov 2025) / 39.83% (31 Mar 2025) |
| EPS | - |
| NAV per share | - |
| Debt to Equity | 2.23 (30 Nov 2025) / 1.02 (31 Mar 2025) |
| P/E Ratio | - |
| Industry P/E | - |
Company Financial Data
| Period | Assets | Total Income | PAT | EBITDA | Net Worth | Borrowings |
|---|---|---|---|---|---|---|
| 30 Nov 2025 | 65.17 Cr | 28.63 Cr | 8.66 Cr | 13.45 Cr | 17.12 Cr | 38.17 Cr |
| 31 Mar 2025 | 39.12 Cr | 38.33 Cr | 9.79 Cr | 15.21 Cr | 14.73 Cr | 15.01 Cr |
| 31 Mar 2024 | 19.53 Cr | 15.34 Cr | 2.50 Cr | 5.63 Cr | 4.94 Cr | 10.49 Cr |
| 31 Mar 2023 | 17.57 Cr | 16.25 Cr | 0.33 Cr | 1.70 Cr | 2.44 Cr | 9.61 Cr |
Grey Market Premium
| GMP Price | N/A (pre-listing) |
| Kostak Rate | N/A |
| Subject to Sauda | N/A |
| Last Updated | May 2026 |
| Estimated Listing Price | N/A |
IPO Subscription Data
| Total Subscription | Pending (IPO opens 21 May 2026) |
| QIB (Ex Anchor) | Pending |
| HNI Subscription | Pending |
| Retail Subscription | Pending |
| Anchor | - |
IPO Intermediaries
Registrar: Skyline Financial Services Pvt. Ltd.
Registrar Website: https://www.skylinerta.com
IPO Lead Manager(s)
Company Information
Address: Plot No. 11B-11C,Sector-E, Sanwer Road Industrial Area, Industrial Estate (Indore),Indore, Madhya Pradesh, 452015
Website: https://biomedica.co.in/
Email: companysecretary@biomedica.co.in
Phone: +91 7314102751
IPO Documents
Frequently Asked Questions (FAQ)
Explore More Investment Opportunities
Discover IPOs, unlisted shares, and broker comparison tools curated for smart investors.